Fig. 1 · Structure

Cat. No.: A10031
CAS No.: 103-84-4
Formula: C₈H₉NO
Mol. Weight: 135.2

Documents & Downloads

Acetanilide

Name: Acetanilide
Brand: Adooq Bioscience
SKU: A10031
Availability: InStock

Cat. No. A10031 CAS 103-84-4

Hydrogen peroxide inhibitor

Acetanilide is used as an inhibitor in hydrogen peroxide and is used to stabilize cellulose ester varnishes.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Acetanilide served as a p-hydroxylation substrate in a reconstituted rabbit liver P-4481 system. Product formation occurred without cytochrome b5 and increased when b5 was added. These results characterize a metabolic substrate reaction; they do not establish selective inhibition of a molecular target. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

Acetanilide p-hydroxylation in a reconstituted P-4481 system

Biochemical assay · Reconstituted monooxygenase system containing P-4481 purified from rabbit liver microsomes [1]

Table III reports p-hydroxyacetanilide formation in standard, cytochrome b5-supplemented and complete systems. Activity was present in the standard system, which lacked cytochrome b5 and NADH-cytochrome b5 reductase.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
p-Hydroxyacetanilide formation: Standard system	Product formation rate 6.25 nmol/min/nmol P-4481	[1]
p-Hydroxyacetanilide formation: Standard system + cytochrome b5	Product formation rate 7.47 nmol/min/nmol P-4481	[1]
p-Hydroxyacetanilide formation: Complete system	Product formation rate 8.54 nmol/min/nmol P-4481	[1]

Literature-Reported Treatment Conditions

Treatment concentration: 5 mM
Exposure duration: 30 min
Method: Reconstituted enzyme assay at 25 °C in 50 mM sodium phosphate buffer, pH 7.25; product measured using Folin–Ciocalteu reagent.
Co-treatment: Assay cofactors included NADPH and NADH (0.1 mM each). Standard system omitted cytochrome b5 and NADH-cytochrome b5 reductase; the complete system included both.
Reported limits: Acetanilide stock solvent, individual replicate count and statistical dispersion are not specified in the selected assay/table.

Methods and source locations

Compound reported in the paper: Acetanilide; Compound label in the paper: Acetanilide substrate

Metabolic substrate behavior in the reported purified rabbit enzyme system; no supplier-specific validation or isoform-exclusivity claim.

p. 352 Materials; p. 353 Assay Methods; pp. 358–359 P-4481 results and Table III

p-Hydroxyacetanilide formation: Standard system: Folin–Ciocalteu product assay; 30 min reaction. — p. 359 Table III, substrate-present row for Standard system; p. 353 Assay Methods

p-Hydroxyacetanilide formation: Standard system + cytochrome b5: Folin–Ciocalteu product assay; 30 min reaction. — p. 359 Table III, substrate-present row for Standard system + cytochrome b5; p. 353 Assay Methods

p-Hydroxyacetanilide formation: Complete system: Folin–Ciocalteu product assay; 30 min reaction. — p. 359 Table III, substrate-present row for Complete system; p. 353 Assay Methods

In Vivo Studies

In male white rabbits, blood measurements after acetanilide administration showed concentration-dependent elimination. The authors described approximately first-order decline below 1 mg% and departure from first-order behavior above 2 mg%. These are pharmacokinetic observations, without an analgesic efficacy endpoint. [2]

Concentration-dependent acetanilide elimination in rabbit blood

Animal study · Unanesthetized male white rabbits [2]

Serial parent-drug blood measurements were compared across doses. The reported apparent first-order rate constant at low blood concentrations was about 1.7 hr−1; higher concentrations showed non-first-order elimination.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Apparent first-order elimination at blood acetanilide concentrations below 1 mg%	Elimination rate constant about 1.7 hr−1	[2]

Conditions shared by the study groups

Route: Intravenous; rabbits D and N received 300 mg orally (Table V footnote a).
Frequency: Single administration
Treatment course: Serial blood measurements tabulated through 5 hr; not every animal has every time point.
Vehicle: Water; Methods describes acetanilide dissolved at 40 °C to make a 300 mg/50 ml solution.

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Acetanilide dose series 30, 100, 200 or 300 mg per rabbit	Comparison across doses and serial time points; no separate vehicle-control group is described for Table V.	Below 1 mg%, decline was approximately log-linear; above 2 mg%, elimination departed from first-order behavior.	[2]

Acetanilide dose series: Model: Male white rabbits; Table V identifies rabbits I, K, S, Z, A, D, G, J, N, Q and W.; Reported limits: Randomization, blinding and inferential statistical tests are not reported in the selected methods/results. The paper contains inconsistent general versus tabulated body weights; no mg/kg conversion is adopted.

Methods and source locations

Compound reported in the paper: Acetanilide; Compound label in the paper: Unchanged acetanilide

Descriptive rabbit parent-drug PK; no clinical dose recommendation or efficacy inference.

p. 1663 Animal, Drug and Analytical Methods; p. 1668 Table V and following paragraph; p. 1669 Fig. 4

Apparent first-order elimination at blood acetanilide concentrations below 1 mg%: Logarithmic plots of parent blood concentrations; linear portions used for rate constants. — p. 1668 paragraph below Table V and Table V rate-constant footnote; p. 1669 Fig. 4

Acetanilide dose series · p. 1663 Animal, Drug and Analytical Methods; p. 1668 Table V and following paragraph; p. 1669 Fig. 4

Specifications

Manufacturer	Adooq Bioscience
Actions	Inhibitor
CAS Number	103-84-4
Applications	Hydrogen peroxide inhibitor
Formula	C₈H₉NO
Molecular Weight	135.2
Synonyms	Acetanil; Acetamidobenzene; Acetylaniline; NSC 7636; acetanilid
SMILES	CC(=O)NC1=CC=CC=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] Imai Y. The roles of cytochrome b5 in reconstituted monooxygenase systems containing various forms of hepatic microsomal cytochrome P-450. Journal of biochemistry (1981). PMID: 6972374 DOI: 10.1093/oxfordjournals.jbchem.a133209 Source material
[2] Shibasaki J, Koizumi T, Tanaka T. Drug absorption, metabolism, and excretion. I. Some pharmacokinetic aspects of metabolism of acetanilide and 4-hydroxyacetanilide. Chemical & pharmaceutical bulletin (1968). PMID: 5709238 DOI: 10.1248/cpb.16.1661 Source material